MedTrace Logo

Xanthine Oxidase Inhibition in Renal Transplant Recipients

NCT01332799 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-10-15

Study results available
· View outcomes & findings →

Summary

Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.

Conditions

  • Complications of Renal Transplant

Interventions

DRUG

allopurinol or placebo

Daily active drug (allopurinol administered orally) administered orally for 3 years.

OTHER

Placebo

Sugar pill administered orally for 3 years.

Sponsors & Collaborators

  • Roberto S Kalil

    lead OTHER

Principal Investigators

  • Roberto S Kalil, MD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2018-08-10
Completion
2018-08-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01332799 on ClinicalTrials.gov